.12 Apr 2018 08:42
Results out... mixed bag... future looks good - one to build on - may sell if spike then buy back later...
FLS:
C4XD's combination of state-of-the-art proprietary technologies, highly experienced scientific team and industry experience, now coupled with experience in completing commercial licensing transactions, uniquely positions the Company to fulfil the pharmaceutical industry's demand for high quality early-stage drug candidates. As the Company accelerates towards its goal of becoming the world's most productive, self-sustaining drug discovery engine, it aims to build on its commercial experience and to continue building a portfolio of commercially attractive pre-clinical assets.
Following the out-licensing of C4XD's Ox-1 programme the Company now has three lead drug discovery programmes compounds showing in vivo activity, opening up a path to candidate selection and opportunity to progress to partnering discussions.